Muscle & Brawn 2.0 is live! New Tools, Voice Reader, Compound Index, Features and more on the way. Want to explore what’s new → Click Here
Independent & reader-supported — every article medically reviewed

Peptides / Longevity and mitochondrial peptides

108 In the index

SS-31 SS-31

A peptide targeted at the energy-producing parts of cells, studied in human trials for rare mitochondrial diseases and a type of heart failure. Results have been mixed, with some trials not meeting their goals, though research continues in specific patient groups.

Also known as Elamipretide, MTP-131, bendavia, Ocuvia, MTP 131, Szeto-schiller peptide, Elamipretida, Nh2-d-arg-dmt-lys-phe-nh2

Effects Endurance Longevity
Routes Subcutaneous
Legal status Unapproved / investigational
WADA Not listed

Molecular Structure of C32H49N9O5

Drag to rotate · scroll to zoom

  • Carbon
  • Hydrogen
  • Nitrogen
  • Oxygen

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula
C32H49N9O5
Molar mass
639.8
CAS
736992-21-5
PubChem CID
11764719
IUPAC name
(2S)-6-amino-2-[[(2S)-2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-N-[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]hexanamide
InChIKey
SFVLTCAESLKEHH-WKAQUBQDSA-N

Reported dosing

User-reported

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not established for humans (as a self-administered product)
Reported range Phase II trial doses (as elamipretide): up to 40 mg/day subcutaneous
Route Subcutaneous injection
Frequency Once daily (trial protocol)
Duration Trial durations of several months

Studied clinically (as elamipretide) for mitochondrial diseases and heart failure with mixed trial results; not FDA-approved. Sold outside trials only as an unregulated research chemical.

Where this comes from Published Phase II/III clinical trial data; user-reported/research-chemical vendor literature

There is no approved human dosing for this compound. The figures above are what users and vendors report, not what has been established as safe or effective. Treat them as a record of what is done, not as guidance.